NLTX

Neoleukin Therapeutics, Inc. (NLTX) | Rumor.io

Neoleukin Therapeutics

NLTX

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about NLTX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% new	0% 0

Jul 18

Neoleukin Therapeutics, Inc. ($NLTX) has proposed a merger with Neurogene, with pre-merger $NLTX stockholders expected to own approximately 16% of the combined company.
The merger agreement, announced on July 18, 2023, will result in Neurogene becoming a wholly owned subsidiary of Neoleukin, with Neurogene stockholders owning approximately 84% of the combined company.
Shares of $NLTX have risen 25% since the merger announcement, trading at $1.16, with some analysts valuing the new company at $200 million, resulting in a potential value of $0.78 per $NLTX share.

Generated by AI

Sentiment

Of the messages about NLTX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	100% +2.56
Bearish	—	—	—	0% -2.56

Bullish· Mar 9

$NLTX is a top pick for after-hour trading, with a potential price target of $1.
The company's strategic alternatives news has led to a 40% after-hours pop, suggesting a potential buyout or significant partnership.
$NLTX's cash conservation efforts and reduced workforce are seen as bullish indicators, with a daily chart target of $0.868.

Bearish· Jul 20

The stock has dipped below its support level at $2.95 and is still declining.
The asset's momentum is weak, with ADX (momentum) significantly below its threshold.
The stock's price may drop to $2, based on current trends.

Generated by AI

Topics

Of the messages about NLTX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	100%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	0%

Announcements· Jul 18

$NLTX will issue shares of Neoleukin common stock in exchange for Neurogene shares, with Neurogene becoming a wholly owned subsidiary of Neoleukin.
Pre-merger $NLTX stockholders are expected to own approximately 16% of the combined company, while Neurogene stockholders will own approximately 84%.
Neoleukin Therapeutics shares jumped 7% on the announcement of the definitive merger agreement with Neurogene.

Technical Analysis· Aug 13

$NLTX has formed a support at the 4ema, potentially leading to another big move.
A close above $20 would be extremely constructive for $NLTX, indicating a potential breakout.
$NLTX is facing resistance at $20.95, with support at $16.33, and needs to break through $20.50 to continue its upward momentum.

Generated by AI

Community

Of the messages about NLTX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	0%	79.49%
Newcomers	100%	100%	100%	20.51%

Regulars· Mar 9

Neoleukin Therapeutics, Inc. (NLTX) is undergoing significant restructuring, including a 70% reduction in staff, as the company searches for a sale or other exit.
The company's shares surged 35% premarket after weighing a potential sale and planning to cut the workforce by 70%.
Neoleukin Therapeutics provided a strategic update, announcing a further corporate restructuring to preserve cash, including a 70% reduction in workforce, which led to a 41% premarket increase in the company's shares.

Newcomers· Mar 9

The company has engaged SVB Securities to review strategic alternatives and is reducing its workforce by 70%, with the reduction expected to be completed by the first half of 2023.
The news has led to a significant increase in the company's share price, with a 40% pop after hours.
The restructuring and leadership transition are expected to be completed in the first half of 2023, with the company providing a strategic update and announcing the changes.

Generated by AI

Also Discussed

Investors talking about NLTX also mention

#	Name	Attention
1	AllianzIM U.S. Equity 6 Month Buffer10 Jun/Dec ETFSIXD	0%0
2	XOMA CorporationXOMA	0%0
3	CERE - Cerevel Therapeutics Holdings, Inc.	——
4	Akari Therapeutics Plc ADRAKTX	0%0
5	AAC - Ares Acquisition Corporation	——
6	SINTX Technologies, Inc. Common StockSINT	0%0
7	NTBL - Notable Labs, Ltd.	——
8	Can-Fite BioPharma Ltd. ADRCANF	0%0
9	Abeona Therapeutics Inc.ABEO	0%+0
10	Element Solutions Inc.ESI	0%0